AveXis (NASDAQ:AVXS) saw some unusual options trading on Tuesday. Stock traders acquired 4,152 call options on the stock. This is an increase of approximately 998% compared to the typical daily volume of 378 call options.

Several brokerages have recently issued reports on AVXS. Citigroup lowered AveXis from a “buy” rating to a “neutral” rating in a report on Tuesday. Credit Suisse Group reiterated a “neutral” rating and set a $139.00 price target on shares of AveXis in a report on Wednesday. Nomura upgraded AveXis from a “reduce” rating to a “neutral” rating in a report on Monday. Morgan Stanley lowered AveXis from an “overweight” rating to a “hold” rating in a report on Monday. Finally, BidaskClub upgraded AveXis from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 10th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. AveXis has an average rating of “Hold” and an average target price of $123.90.

How to Become a New Pot Stock Millionaire

AVXS opened at $211.85 on Thursday. AveXis has a twelve month low of $65.54 and a twelve month high of $213.70. The company has a market capitalization of $7,729.23, a P/E ratio of -29.10 and a beta of 2.06.

AveXis (NASDAQ:AVXS) last posted its earnings results on Tuesday, February 27th. The company reported ($2.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.64) by ($0.91). analysts predict that AveXis will post -7.63 earnings per share for the current year.

In other news, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $118.07, for a total transaction of $1,771,050.00. Following the completion of the sale, the insider now directly owns 1,792,147 shares in the company, valued at approximately $211,598,796.29. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Sean P. Nolan sold 10,000 shares of AveXis stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $129.47, for a total value of $1,294,700.00. Following the sale, the chief executive officer now owns 10,000 shares of the company’s stock, valued at $1,294,700. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 68,780 shares of company stock worth $8,341,178. Company insiders own 18.60% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of AVXS. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in AveXis by 57.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock worth $137,000 after purchasing an additional 453 shares during the last quarter. QS Investors LLC acquired a new stake in AveXis in the 4th quarter worth approximately $156,000. Cubist Systematic Strategies LLC lifted its holdings in AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after purchasing an additional 1,577 shares during the last quarter. Prudential Financial Inc. acquired a new stake in AveXis in the 3rd quarter worth approximately $224,000. Finally, Vident Investment Advisory LLC acquired a new stake in AveXis in the 3rd quarter worth approximately $245,000. Hedge funds and other institutional investors own 82.43% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Traders Buy Large Volume of Call Options on AveXis (AVXS)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/traders-buy-large-volume-of-call-options-on-avexis-avxs/2017908.html.

About AveXis

AveXis, Inc, a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1.

Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.